What is Leerink Partnrs’ Estimate for TNDM FY2027 Earnings?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Tandem Diabetes Care in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky expects that the medical device company will earn ($0.01) per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2028 earnings at $0.27 EPS.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $221.90 million during the quarter, compared to the consensus estimate of $205.63 million. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.30) earnings per share.

Several other equities analysts also recently issued reports on TNDM. Barclays raised their price target on shares of Tandem Diabetes Care from $55.00 to $58.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. The Goldman Sachs Group initiated coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 price target for the company. UBS Group upgraded shares of Tandem Diabetes Care to a “hold” rating in a research report on Friday, August 2nd. Wells Fargo & Company increased their price objective on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $45.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.13.

Tandem Diabetes Care Price Performance

TNDM stock opened at $34.81 on Thursday. The company has a fifty day moving average price of $42.02 and a 200-day moving average price of $41.84. The company has a market capitalization of $2.28 billion, a P/E ratio of -16.66 and a beta of 1.33. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $53.69. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05.

Institutional Investors Weigh In On Tandem Diabetes Care

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in Tandem Diabetes Care by 1,481.5% in the first quarter. BNP Paribas Financial Markets now owns 145,812 shares of the medical device company’s stock worth $5,163,000 after purchasing an additional 136,592 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Tandem Diabetes Care during the first quarter valued at about $540,000. Vanguard Group Inc. grew its holdings in shares of Tandem Diabetes Care by 0.4% during the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after buying an additional 30,664 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Tandem Diabetes Care during the first quarter valued at about $5,227,000. Finally, Quantbot Technologies LP acquired a new position in shares of Tandem Diabetes Care during the first quarter valued at about $710,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.